Impact of COX2 on Sera Biomarkers From Obese Subjects
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | October 2013 |
| End Date: | January 2016 |
| Contact: | Epp Goodwin |
| Email: | CTRCReferral@uthscsa.edu |
| Phone: | 210-450-5798 |
A Phase 0, Investigator Initiated Study, Evaluating the Impact of COX2 Inhibition on Human Sera Biomarkers From Obese Subjects
Obesity promotes worse outcome for post-menopausal breast cancer patients.
Inclusion Criteria:
- At least 18 years of age
- Post-menopausal as confirmed by medical history
- Ability to understand the purposes and risks of the study and has signed a written
informed consent form approved by the investigator's IRB/Ethics Committee
Exclusion Criteria:
- Evidence of active cancer (patients with a prior history of malignancy are encouraged
to participate, but due to cytokine levels associated with malignancy there must be
no evidence of disease)
- Cachexia
- Active systemic illness (infection including viral illnesses such as Hepatitis and
HIV)
- Chronic use of aspirin of omega-3 free fatty acid supplementation within the last 60
days (defined as greater than or equal to 7 consecutive days)
- Known hypersensitivity to aspirin and/or omega-3 fatty acids
- Actively receiving a physician-directed regimen of aspirin and/or receiving
herapeutic/prophylactic anticoagulation
- Any aspirin or omega-3 free fatty acid supplementation within the last 14 days
- Subjects who are pregnant
- History of medical noncompliance
We found this trial at
1
site
San Antonio, Texas 78229
Principal Investigator: Andrew Brenner, MD
Phone: 210-450-5798
Click here to add this to my saved trials
